logo

COCH

Envoy Medical·NASDAQ
--
--(--)
--
--(--)
1.08 / 10
Underperform

Fundamental evaluation is challenging (score 1.1/10). Key weaknesses include negative Net income-Revenue (-0.1668) and Cash-MV (-0.0673) ratios, a very low ROA (-174.15%), and an Interest coverage ratio of only 15.48%, indicating limited cushion for debt. While Cash-UP shows a slight positive (-0.0574), it is outweighed by other deficits, leading to an overall underperform rating.

Fundamental(1.08)SentimentTechnical

Analysis Checks(3/10)

Revenue-MV
Value-4.61
Score2/3
Weight-0.27%
1M Return0.09%
ROA (%)
Value-174.15
Score0/3
Weight15.63%
1M Return-7.78%
Net profit attributable to parent company shareholders / Net profit (%)
Value121.87
Score1/3
Weight10.86%
1M Return-3.49%
Net income-Revenue
Value-0.17
Score1/3
Weight7.41%
1M Return-2.55%
Cash-UP
Value-0.06
Score2/3
Weight12.80%
1M Return-4.86%
Annualized net profit margin on total assets (%)
Value-232.20
Score0/3
Weight15.63%
1M Return-7.78%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight5.92%
1M Return-1.95%
Asset-MV
Value-0.50
Score0/3
Weight9.92%
1M Return-3.57%
Cash-MV
Value-0.07
Score1/3
Weight14.06%
1M Return-5.64%
Net profit / Total profit (%)
Value100.00
Score1/3
Weight8.03%
1M Return-2.89%
Is COCH undervalued or overvalued?
  • COCH scores 1.08/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -10475.00% net margin, -0.48 P/E ratio, -1.80 P/B ratio, and -17.09% earnings growth, these metrics solidify its Underperform investment rating.